The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform

L A Geraskina - One of the best experts on this subject based on the ideXlab platform.

  • Antithrombocytic THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE
    IMA-PRESS LLC, 2009
    Co-Authors: Andrey Viktorovich Fonyakin, L A Geraskina
    Abstract:

    Approaches to preventing recurrent stroke by Antithrombocytic therapy are shown to be as diverse as its causes. The diagnosis of cardioembolic stroke in patients with atrial fibrillation should not limit the choice of an Antithrombocytic Agent to only oral (indirect) anticoagulants (OAC). If OAC cannot be used, Antithrombocytic therapy, including combined (clopidogrel + ASA) one, may be considered as a reasonable alternative. Approaches to choosing the optimal Antithrombocytic drug in noncardioembolic strokes are intricate since atherosclerosis is a systemic vascular disease and the poststroke period is characterized by a higher risk for not only recurrent stroke, but also for coronary catastrophes. It is concluded that an Antithrombocytic Agent should be chosen, by taking into account the multifocality of atherosclerosis, associated clinical conditions, diabetes mellitus, intravascular interventions and the individual risk of all cardiovascular events

Andrey Viktorovich Fonyakin - One of the best experts on this subject based on the ideXlab platform.

  • Antithrombocytic THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE
    IMA-PRESS LLC, 2009
    Co-Authors: Andrey Viktorovich Fonyakin, L A Geraskina
    Abstract:

    Approaches to preventing recurrent stroke by Antithrombocytic therapy are shown to be as diverse as its causes. The diagnosis of cardioembolic stroke in patients with atrial fibrillation should not limit the choice of an Antithrombocytic Agent to only oral (indirect) anticoagulants (OAC). If OAC cannot be used, Antithrombocytic therapy, including combined (clopidogrel + ASA) one, may be considered as a reasonable alternative. Approaches to choosing the optimal Antithrombocytic drug in noncardioembolic strokes are intricate since atherosclerosis is a systemic vascular disease and the poststroke period is characterized by a higher risk for not only recurrent stroke, but also for coronary catastrophes. It is concluded that an Antithrombocytic Agent should be chosen, by taking into account the multifocality of atherosclerosis, associated clinical conditions, diabetes mellitus, intravascular interventions and the individual risk of all cardiovascular events